Cyclosporine protects from apoptosis-mediated epithelial damage through epithelial STAT3 signaling pathway
Project/Area Number |
26460957
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Gastroenterology
|
Research Institution | Hirosaki University |
Principal Investigator |
|
Research Collaborator |
HIRAGA Hiroto 弘前大学, 大学院医学研究科, 助教 (80637546)
|
Project Period (FY) |
2014-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Keywords | 炎症性腸疾患 / IL-22受容体 / TGF-beta / シクロスポリン / 腸上皮細胞 / アポトーシス / 腸管上皮細胞 / 腸上皮アポトーシス / TGF-β / STAT-3 / STAT3 |
Outline of Final Research Achievements |
Treatment of cyclosporine ameliorated mucosal destruction through reduction of epithelial apoptosis in DSS-induced colitis model. IL-22 receptor expression and STAT3 phosphorylation in purified intestinal epithelial cells (IECs) were up-regulated in cyclosporine but not in vehicle treated mice. Anti-TGF-beta mAb treatment diminished the protective effect of cyclosporine. In addition, anti-TGF-beta mAb treatment diminished up-regulated IL-22 receptor expression and STAT3 phosphorylation in IECs. In Caco2 cells, the treatment with both cyclosporine and recombinant TGF-beta increased IL-22 receptor expression. These results demonstrate that treatment of cyclosporine can ameliorate apoptosis-mediated epithelial damage through epithelial IL-22 receptor-STAT3 signaling pathway, which required the TGF-beta stimulation.
|
Report
(5 results)
Research Products
(1 results)